Mark Lackner - 02 Jan 2025 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Scientific Officer
Signature
/s/ Andrea Paul, attorney-in-fact for Mark Lackner
Issuer symbol
ZNTL
Transactions as of
02 Jan 2025
Transactions value $
-$13,762
Form type
4
Filing time
03 Jan 2025, 17:17:05 UTC
Previous filing
05 Feb 2024
Next filing
05 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$13.8K -4.41K -2.25% $3.12 191K 02 Jan 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.